Cell Identity and Signaling (CIS)

Cell Identity and Signaling（CIS）研究计划 项目摘要 细胞身份和信号（CIS）研究计划的主要科学目标是推进发现 细胞身份和细胞信号传导的新分子机制，将这些知识应用于理解 癌症发病机制，并利用这些知识开发新的，基于机制的方法，以预防或 干扰癌细胞的生长，旨在癌症的解决方案。众所周知，癌细胞劫持了正常细胞， 通过遗传和表观遗传机制调节细胞生长、分化和胚胎发育。 CIS计划旨在了解这些基本机制，并引导他们走向癌症 解决方案 CIS计划有27个成员，550万美元的癌症为重点，同行评审的校外资金， 38%的资金来自NCI。CIS的研究主题涵盖了从基本发现到使用简单 模型生物体和细胞及动物癌症模型，到癌症解决方案。独联体成员国生产力很高 自2015年7月以来，有202篇与癌症相关的出版物，并且高度互动，合作增加了70%。 出版物。重要的是，所有癌症相关的CIS出版物中有73%是合作的。在此前的融资中， 周期，CIS计划，由普渡癌症研究中心的竞争性试点赠款支持 （PCCR），成功地促进了高度合作，癌症相关的研究，联系独联体计划的主题（内部， 与其他PCCR计划（计划间）以及外部合作伙伴（计划间）合作， 机构）。 对于下一个资助期，CIS计划的目标是推进我们的 了解癌症相关机制，并最大限度地过渡到癌症解决方案。的方法 实现这一目标是通过提供竞争力，使和促进合作和跨学科研究 PCCR试点赠款，以及获得最先进的PCCR支持的共享资源和现代技术 结构生物学、药物发现、癌症基因组学、生物信息学和计算生物学。三个具体 提出了目标。目的1：通过以下方法进一步加强基本和癌症相关机制的发现： 加强计算基因组学和生物信息学的整合，增加专门知识和培训 在计算生物学中。目的2：促进发现癌症相关的信号转导机制， 基因表达和表观遗传学的支持合作，跨学科的方法和现代 技术.目标3：加速新发现的癌症相关机制向癌症的转变 解决方案，通过开发作为治疗目标的基本机制，并采用跨学科的方法， 接近。

Cell Identity and Signaling (CIS) Research Program Project Summary The key scientific goals of the Cell Identity and Signaling (CIS) Research Program are to advance discovery of novel molecular mechanisms of cell identity and cell signaling, to apply this knowledge towards understanding cancer pathogenesis, and to use this knowledge to develop novel, mechanism-based approaches to prevent or interfere with cancer cell growth, aiming for cancer solutions. It is well-established that cancer cells hijack normal regulation of cell growth, differentiation, and embryonic development, via genetic and epigenetic mechanisms. The CIS Program aims to understand these fundamental mechanisms and shepherd them toward cancer solutions. The CIS Program has 27 members, $5.5 million in cancer-focused, peer-reviewed extramural funding, with 38% of the total funding from the NCI. CIS research themes span a spectrum from basic discovery, using simple model organisms and cellular and animal cancer models, to cancer solutions. CIS members are highly productive with 202 cancer-related publications since July 2015, and highly interactive with a 70% increase in collaborative publications. Importantly, 73% of all cancer-relevant CIS publications are collaborative. In the previous funding cycle, the CIS Program, supported by competitive pilot grants from the Purdue Center for Cancer Research (PCCR), successfully fostered highly collaborative, cancer-relevant studies linking CIS Program themes (intra- programmatic) with other PCCR programs (inter-programmatic), and also with external partners (inter- institutional). For the next funding period, the goal of the CIS Program is to advance the breadth and depth of our understanding of cancer-relevant mechanisms and to maximize their transition to cancer solutions. The approach towards this goal is to enable and foster collaborative and transdisciplinary studies by providing competitive PCCR pilot grants, and access to state-of-the-art, PCCR-supported Shared Resources, and modern technology in structural biology, drug discovery, cancer genomics, bioinformatics and computational biology. Three specific aims are proposed. Aim 1: To further enhance discovery of basic and cancer-relevant mechanisms by strengthening the integration of computational genomics and bioinformatics and increasing expertise and training in computational biology. Aim 2: To enhance discovery of cancer-relevant mechanisms of signal transduction, gene expression and epigenetics by supporting collaborative, transdisciplinary approaches and modern technologies. Aim 3: To accelerate transition of newly discovered cancer-relevant mechanisms towards cancer solutions, by developing essential mechanisms as therapy targets, and by employing transdisciplinary approaches.